Journal
BIOSENSORS-BASEL
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/bios12060412
Keywords
interleukin-6; array SPRi; cancer biomarkers; ovarian cancer; blood plasma
Funding
- Polish Ministry of Education and Science [BST-162]
Ask authors/readers for more resources
Interleukin-6 (IL-6) is a biomarker for inflammation, COVID-19, and various cancers including ovarian cancer. Two biosensors were developed for detecting IL-6 in blood plasma and validated for clinical application.
Interleukin-6 (IL-6) is a biomarker of inflammation, the advanced stage of COVID-19, and several cancers, including ovarian cancer. Two biosensors for the determination of IL-6 in blood plasma by array SPRi have been developed. One of these biosensors consists of the mouse monoclonal anti-IL-6 antibody as the receptor immobilized via the cysteamine linker. The second contains galiellalactone as the receptor, being an inhibitor specific for IL-6, immobilized via octadecanethiol (ODM) as the linker. Both biosensors are specific for IL-6. The biosensor with the antibody as the receptor gives a linear analytical response between 3 (LOQ) and 20 pg mL(-1) and has a precision between 8% and 9.8% and recovery between 97% and 107%, depending on the IL-6 concentration. The biosensor with galiellalactone as the receptor gives a linear analytical response between 1.1 (LOQ) and 20 pg mL(-1), and has a precision between 3.5% and 9.3% and recovery between 101% and 105%, depending on IL-6 concentration. Both biosensors were validated. Changes in IL-6 concentration in blood plasma before and after resection of ovarian tumor and endometrial cyst, as determined by the two developed biosensors, are given as an example of a real clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available